The DOI matches its Crossref record; the references it cites are not checked yet.
Expanding targeted therapy for lung cancer
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Although molecularly targeted therapies and immunotherapies have expanded treatment options for LUAD, overall response rates remain unsatisfactory, and treatment resistance and adverse effects continue to limit durable clinical outcomes.
“Although the emergence of molecularly targeted therapies and immunotherapies has expanded treatment options for LUAD, overall response rates remain unsatisfactory, and treatment resistance and adverse effects continue to limit durable clinical outcomes (4, 5).”
From Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma (2026) · cites this paper as [4]
Citations
The citation lists haven’t been fetched yet
References 9 · Cited by 2
Research works printed but not linked: 7
- Gomez-Randulfe, I., Monaca, F., Planchard, D., Bria, E. & Califano, R. Crit. Rev. Oncol. Hematol. 212, 104762 (2025). · DOI
- Pons Tostivint, E. et al. J. Thorac. Oncol. 20 (Suppl. 1), S30–S31 (2025). · DOI
- Ismail, A., Desai, A. & Boumber, Y. Front. Oncol. 15, 1624124 (2025). · DOI
- Heymach, J. V. et al. N. Engl. J. Med. 392, 2321–2333 (2025). · DOI · Paper page
- Li, Z. et al. Lancet Oncol. 26, 437–446 (2025). · DOI
- Fang, W. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2512071 (2025). · DOI
- Garassino, M. C. et al. J. Thorac. Oncol. 19, abstr. PL02.11 (2024). · DOI
Metadata
- Authors
- Ballard, W., Agarwal, M., & Liu, S. V.
- Affiliations
- Georgetown University (US)
- Corresponding author
- Liu, Stephen V.
- Venue
- Nature Cancer
- Published
- 2025-12-10
- Volume
- 6
- Issue
- 12
- Pages
- 1916-1917
- ISSN
- 2662-1347 (ISSN-L)
- OpenAlex
- W4417208852
- Cited by
- 2
- References
- 9
- Citations by year
- 2026: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- non-small cell lung cancer, targeted therapy, antibody-drug conjugates, tyrosine kinase inhibitors, FDA drug approval, molecular subtypes, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
